The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy.
M. E. Lacouture
Consultant or Advisory Role - Roche
Honoraria - Roche
P. B. Chapman
Consultant or Advisory Role - Roche
Research Funding - Roche
A. Ribas
Consultant or Advisory Role - Roche
Honoraria - Roche
J. A. Sosman
Consultant or Advisory Role - Genentech; Roche
Honoraria - Genentech; Roche
G. A. McArthur
Consultant or Advisory Role - Genentech (U)
K. T. Flaherty
No relevant relationships to disclose
K. B. Kim
No relevant relationships to disclose
I. Puzanov
No relevant relationships to disclose
K. B. Nolop
No relevant relationships to disclose
A. K. Joe
Employment or Leadership Position - Roche
O. Spleiss
Employment or Leadership Position - Roche
A. Koehler
Employment or Leadership Position - Roche
W. Wu
Employment or Leadership Position - Roche
C. Robert
Consultant or Advisory Role - Roche
A. Hauschild
Consultant or Advisory Role - GlaxoSmithKline; Roche
Honoraria - GlaxoSmithKline; Roche
Research Funding - Roche
D. Schadendorf
No relevant relationships to disclose
J. L. Troy
Consultant or Advisory Role - Roche
M. Duvic
No relevant relationships to disclose
K. Trunzer
No relevant relationships to disclose